• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    2/9/23 11:27:43 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    SC 13G/A 1 tv01487-naturessunshineprodu.htm SCHEDULE 13G/A naturessunshineproductsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Nature's Sunshine Products Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  639027101

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  639027101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    6,900

    7.  SOLE DISPOSITIVE POWER

    466,652

    8.  SHARED DISPOSITIVE POWER

    10,724

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    477,376

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.49%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Nature's Sunshine Products Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2901 West Bluegrass Boulevard, Suite 100
    Lehi, UT 84043

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    639027101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $NATR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nature's Sunshine Products Inc.

      10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 5:10:24 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      5/6/25 4:38:55 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nature's Sunshine Products Inc.

      DEF 14A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

      3/20/25 10:09:21 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DA Davidson resumed coverage on Nature's Sunshine with a new price target

      DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

      5/7/25 8:37:48 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

      Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

      9/13/24 7:38:59 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

      DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

      3/9/22 9:23:08 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    See more
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Katie A. May to Board of Directors

      LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine serving as independent directors. "Katie brings significant experience scaling and leading high-growth B2C, ecommerce and logistics companies," said Richard D. Moss, Chairman of the Board of Nature's Sunshine. "Her deep understanding of the full ecommerce lifecycle will strengthen and enhance our digital capabilities and drive s

      2/5/25 4:05:00 PM ET
      $NATR
      $PBI
      $STMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Office Equipment/Supplies/Services
      Miscellaneous
    • Nature's Sunshine Appoints Steven Fasching to Board of Directors

      LEHI, Utah, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Mr. Steven Fasching to its board of directors, effective November 6, 2024. Nature's Sunshine's board will now consist of nine directors with eight serving as independent directors. "We are delighted to welcome Steve to our expanded board of directors," said Richard D. Moss, Chairman of the Board for Nature's Sunshine. "He brings significant financial acumen and public company experience from well-known consumer brands and will be a valuable addition to our board. Ste

      11/11/24 4:05:00 PM ET
      $DECK
      $NATR
      Shoe Manufacturing
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fasching Steven J. was granted 8,000 shares, increasing direct ownership by 279% to 10,869 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/7/25 1:25:23 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Straus Robert D was granted 8,000 shares, increasing direct ownership by 18% to 52,014 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:40 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Roering Tess was granted 8,000 shares, increasing direct ownership by 36% to 29,927 units (SEC Form 4)

      4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

      5/6/25 3:42:30 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/12/24 10:37:49 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      1/31/24 11:56:05 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

      SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

      2/13/23 2:42:04 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Appoints Heidi Wissmiller as Chairman of the Board

      LEHI, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the appointment of Heidi Wissmiller as Chairman of the Board of Directors, effective April 30, 2025. She succeeds Richard D. Moss, who has retired after serving as a Director since 2018 and Chairman since 2022. Ms. Wissmiller has served on the Board of Nature's Sunshine since 2020. Over the course of her tenure, she has chaired the Governance and Risk Management Committees. As Chief Growth Officer at Rodan + Fields ("R+F"), the leading skincare brand in North America, Ms. Wissmiller led

      5/5/25 8:00:00 AM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Wins Two Stevie® Awards in the 2025 American Business Awards®

      LEHI, Utah, April 24, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced it has been recognized with two prestigious Stevie® Awards in the 23rd Annual American Business Awards®. Nature's Sunshine received a Gold Stevie® Award for its 2023 Impact Report, which detailed the Company's achievements and progress in responsible business practices and sustainability. Additionally, the Company earned a Silver Stevie® Award for Achievement in Product Innovation for its new Chlorophyll Detoxifying Stick Packs. "We are deeply honored to be recognized by the American Business Awards," sai

      4/24/25 1:52:06 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NATR
    Financials

    Live finance-specific insights

    See more
    • Nature's Sunshine Reports Strong First Quarter 2025 Results

      LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million. Capital Allocation Na

      5/6/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Sets First Quarter 2025 Conference Call for Tuesday, May 6, 2025, at 5:00 p.m. ET

      LEHI, Utah, April 22, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, May 6, 2025, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2025. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, May 6, 2025Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free di

      4/22/25 4:04:59 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nature's Sunshine Reports Fourth Quarter and Full Year 2024 Financial Results

      LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency).GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share.Adjusted EBITDA up 6% to $10.3 million com

      3/11/25 4:05:00 PM ET
      $NATR
      Biotechnology: Pharmaceutical Preparations
      Health Care